Protecting the Cold Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Protecting the Cold Chain
Makers of temperature-sensitive products constantly seek to ensure proper conditions during shipping and storage.


Pharmaceutical Technology


Insulated packaging


Vacuum-insulated panels and liquid refrigerant packs help the "Golden Hour Platelet Shipper" triple the length of time contents remain at the proper temperature.
Sensitive products generally require specialized packaging that may also include provisions for ice, dry ice, or gel packs. One new option designed for blood-platelet shipments features vacuum-insulated panels and liquid-refrigerant packs to maintain the US Food and Drug Administration's required temperature range of 20–24 °C for two days in both summer and winter conditions. The result is a shelf life that is at least three times that achieved with traditional insulated shippers ("Golden Hour Platelet Shipper," Minnesota Thermal Science, Plymouth, MN).

A prequalified insulated shipping container maintains a temperature range of 2–8 °C for 24 h and conforms to summer and winter weather shipping-condition requirements set by the International Safe Transit Association (ISTA, East Lansing, MI) in its ISTA 7d standard. For more stringent applications, 48-, 72- and 96-h versions are available ("TimeSaver 24," TCP Reliable, Edison, NJ).

Another prequalified thermal shipper capable of maintaining 2–8 °C conditions combines polyurethane construction with refrigerants to provide protection for as many as five days and a 2744-in.3 payload ("Large-Capacity KoolTemp GTS-120" insulated container, Cold Chain Technologies, Holliston, MA).

To minimize environmental impact and reduce waste, Talecris Biotherapeutics, Inc. (Research Triangle Park, NC) specifies a shipping container that combines a recyclable corrugated box with interior insulation panels made of several natural minerals that are heated, spun into a fiber, and encapsulated in biodegradable plastic. "The integration of 'Control Temp Blue' containers into our supply chain will enhance the integrity of our products and minimize any environmental impact from packaging and shipping," says Jim Bacon, director of global demand planning and customer operations at Talecris. Besides the environmental benefits, the new containers offer longer temperature maintenance per inch of insulation, enhanced cushioning, and shock protection for Talecris's glass-packed products ("Control Temp Blue" container, R.N.C. Industries, Inc., Norcross, GA).

Several firms offer insulated bags that maintain product temperature for several hours. Generic insulated medical pouches rely on a three-layer structure consisting of reflective film, polyethylene foam, and food-grade film. The pouches are available in five stock sizes ranging from 12 X 10 in. to 21 X 21 in. This construction also blocks potentially damaging ultraviolet light. Custom designs of the washable, reusable, and recyclable bags can be printed in 10 colors. For added protection, a gel pack can be built into the bag ("Medtraveller" thermal bags, Coldkeepers, LLC, Thomasville, GA).

Another supplier of insulated bags and pouches recently installed a production machine that handles narrow webs of material to meet rising demand for smaller sizes. Bags and pouches are not only certified to be made of food-grade materials, but also provide unit-level traceability because each one carries a unique identification number ("Criomed" and "Criomed Plus" insulated bags, Termika US, Roswell, GA).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here